Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019 (RESCUE)
Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Escalation and Proof-of-Concept Study to Evaluate the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019
Sponsor: EyePoint Pharmaceuticals, Inc.
Terminated
After completion of Step 1 Part 1, the Sponsor discontinued the study based on challenges associated with recruiting and monitoring patients in the current pandemic environment.
Other terminated trials from EyePoint Pharmaceuticals, Inc.
More terminations from EyePoint Pharmaceuticals, Inc.
Other Acute Respiratory Distress Syndrome (ARDS) trials with similar outcome
Browse all Acute Respiratory Distress Syndrome (ARDS) trials
A PHASE2 clinical study on Acute Respiratory Distress Syndrome (ARDS) and COVID-19, this trial is terminated or withdrawn. The trial is conducted by EyePoint Pharmaceuticals, Inc. and has accumulated 11 data snapshots since 2020. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jul 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jul 2023 [monthly]
Terminated PHASE2
▶ Show 6 earlier versions
-
Sep 2021 — Dec 2021 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Nov 2020 — Dec 2020 [monthly]
Recruiting PHASE2
-
Oct 2020 — Nov 2020 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2020 — Oct 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- EyePoint Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .